Navigation Links
MGB Biopharma to Present at Bio-Europe 2013
Date:11/4/2013

cular our lead candidate MGB-BP-3 has shown significant antibacterial activity against a range of Gram positive pathogens and we expect to announce further progress with our on-going programs with MGB-BP-3 in the coming months."

Details of the presentation are as follow:

Title: Infectious Diseases Presentation stream: MGB Biopharma Limited

Time: 10.15am

Location: Level 1, Schubert 4

Venue: Messe Wien Exhibition and Congress Center

About MGB Biopharma

MGB Biopharma is developing a truly novel class of anti-infectives. MGB's lead candidate, MGB-BP-3, is a broad spectrum antibacterial which is active against key multi-resistant Gram positive pathogens. The Company has developed an oral formulation of MGB-BP-3 for Clostridium difficile that is ready to enter the clinic, while an IV formulation for a range of Gram positive infections is in late-stage preclinical development.

MGB's anti-infective drug development capabilities are driven by its broad anti-infective platform, which has the potential to generate truly novel compounds active against other infectious diseases such as Gram negative pathogens as well parasites and fungi.

MGB's anti-infectives are based on minor groove binders (MGBs). Minor groove binders have a new mode of action that offers significant advantages over existing anti-infectives, such as being more bactericidal and active against a broad range of drug-resistant bacteria.

MGB has close links with the University of Strathclyde, with exclusive worldwide licence rights to Strathclyde's MGB patents for all fields expect anticancer. The Company intends to work with partners to fully capitalize on the multiple value creating opportunities offered by its broad and novel anti-infectives platform.

The Company was founded in 2010 and is headquartered in Glasgow, Scotland. It is backed by Scotland's
'/>"/>

SOURCE MGB Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
2. PDL BioPharma to Announce Third Quarter 2013 Financial Results on November 6, 2013
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Says Frost & Sullivan
5. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
6. CDISC and TransCelerate BioPharma Inc. Announce Landmark Asthma Data Standard Released for Public Review
7. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
8. Therapure Biopharma Inc. wins a 2013 CMO Leadership Award in All 5 Categories: Quality, Reliability, Innovation, Productivity and Regulatory
9. Recently Patented Technology Poised To Disrupt The Plasma Biopharmaceutical Market
10. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
11. KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Dec. 9 BioMarin Pharmaceutical,Inc. (Nasdaq: ... partner Merck Serono, a division,of Merck KGaA, ... (sapropterin dihydrochloride) for the treatment of,hyperphenylalaninemia (HPA) ... the European Commission. Merck Serono estimates ...
... DCTH ) today announced the appointment of Roger G. ... Executive Chairman of Cortex Pharmaceuticals, Inc. (Amex: COR ), ... disorders. , , (Logo: ... Prior to joining Cortex, Dr. Stoll worked as a consultant ...
... Md., Dec. 9 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,announced ... of ENMD-2076 in refractory,multiple myeloma patients. The study ... Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. ...
Cached Biology Technology:Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 2EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 3EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 4
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
(Date:8/20/2014)... Health has awarded the Oklahoma Medical Research Foundation a ... anthrax and the bacteria,s effects on humans. , ... his colleagues have studied the human immune response to ... Human Immunology. The original funding came soon after anthrax-laced ... of the terrorist attacks of Sept. 11, 2001. ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2$14.5 million grant awarded to continue anthrax studies 2
... Rome, Italy: Researchers have developed a way of accurately ... blood test. The average difference between the predicted age and ... the menopause was only a third of a year, and ... years. Dr Fahimeh Ramezani Tehrani will tell the 26th ...
... new technology that allows scientists to monitor how individual cells ... researchers have uncovered a much larger spectrum of differences between ... act in a uniform fashion, as was previously thought. ... Markus Covert, PhD, assistant professor of bioengineering and senior author ...
... 27th, 2010 The Elsevier Foundation, TWAS and TWOWS ... scientists from Africa, the Middle East, Asia, Latin America ... was made at the Third World Organization for Women ... Women Scientists in a Changing World, hosted by the ...
Cached Biology News:Researchers develop accurate way to predict the age when women will hit the menopause 2Researchers develop accurate way to predict the age when women will hit the menopause 3Same types of cell respond differently to stimulus, Stanford study shows 2Same types of cell respond differently to stimulus, Stanford study shows 312 women scientists announced as winners of Elsevier Foundation TWOWS Awards 2
... Ambion's custom siRNA service provides the premium ... silencing research. Custom siRNAs can be readily ... base target sequence, or by providing the ... out Ambion's Silencer Validated and Silencer Pre-designed ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Biology Products: